Pricing Log in Create free account

Amylyx Pharmaceuticals, Inc. (AMLX) vs Regencell Bioscience Holdings Limited (RGC)

Amylyx Pharmaceuticals, Inc. and Regencell Bioscience Holdings Limited are both Drug Manufacturers Specialty & Generic companies. Regencell Bioscience Holdings Limited is the larger, with a market value of $4.7B against $3.5B — 1.4× the size. Across the 7 metrics below, Regencell Bioscience Holdings Limited leads on 4 and Amylyx Pharmaceuticals, Inc. on 3.

Valuation

Metric AMLX RGC Drug Manufacturers Specialty & Generic median
P/E n/m n/m 19.25
P/S 33.52 n/m 2.11
P/B 12.25 n/m 1.78
Price to free cash flow n/m n/m 16.14
EV/EBITDA n/m 0.19 12.58
EV/Sales 30.67 n/m 2.73
Earnings yield (5.43%) (10.74%) (4.38%)
Free cash flow yield (4.46%) 0.00% 0.00%

Profitability

Metric AMLX RGC Drug Manufacturers Specialty & Generic median
Gross margin (42.65%) — 53.94%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (74.73%) 0.00% (0.40%)
Return on assets (66.25%) 0.00% (3.32%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AMLX RGC Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (77.06%) — 10.01%
EPS growth (last fiscal year) 65.46% (229.17%) 49.06%
Revenue growth, 5-year CAGR — — 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AMLX RGC Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.00 0.05
Current ratio 12.12 1.42 2.31
Net debt to EBITDA 2.00 1.22 0.97

Dividend

Metric AMLX RGC Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.57%
Payout ratio — — 0.27

Size

Metric AMLX RGC Drug Manufacturers Specialty & Generic median
Market cap 3.47b 4.72b 276.90m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack